A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Cancer Investigation

Volumn 28, Issue 2, 2010, Pages 208-215

  Stinchcombe, Thomas E ^a   Bradford, Daniel S ^b   Hensing, Thomas A ^c   LaRocca, Renato V ^d   Saleh, Mansoor ^e   Evans, Tracey ^f   Bakri, Kamal ^g   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Highlands Oncology Group   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d Kentuckiana Cancer Institute   (United States)

^e Georgia Cancer Specialists   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Cape Fear Valley Health System   (United States)

Author keywords

Clinical trial; Epidermal growth factor receptor (EGFR); First line therapy; Lung cancer; Platinum based

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DIPHENHYDRAMINE; GEMCITABINE; NAVELBINE; PLATINUM; TAXANE DERIVATIVE;

ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77149127367     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903286958     Document Type: Article

References (39)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J Clin 2008, 58, 71-96.
2. Govindan, R.; Page, N.; Morgensztern, D.; Read, W.; Tierney, R.; Vlahiotis, A.; Spitznagel, E.L.; Piccirillo, J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24, 4539-4544.
3. Yang, P.; Allen, M.S.; Aubry, M.C.; Wampfler, J.A.; Marks, R.S.; Edell, E.S.; Thibodeau, S.; Adjei, A.A.; Jett, J.; Deschamps, C. Clinical features of 5,628 primary lung cancer patients: experience at Mayo clinic from 1997 to 2003. Chest 2005, 128, 452-462.
4. Pfister, D.G.; Johnson, D.H.; Azzoli, C.G.; Sause, W.; Smith, T.J.; Baker, S.; Olak, J.; Stover, D.; Strawn, J.R.; Turrisi, A.; Somerfield, M.R. American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22, 330-353.
5. Schiller, J.; Harrington, D.; Belani, C.; Langer, C, Sandler, A.; Krook, J.; Zhu, J.; Johnson, D. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002, 346, 92-98. (Pubitemid 34438899)
6. Treat, J.; Belani, C.P.; Edelman, M.J.; Socinski, M.A.; Ansari, R.H.; Obasaju, C.K.; Bloss, J.D., Marinucci, D.M.; Catalano, R.B.; Comis, R.L. A randomized phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the alpha oncology trial (A1-99002L). J Clin Oncol 2005, 23, abstract 7025, 627s.
7. Scagliotti, G.V.; De Marinis, F.; Rinaldi, M.; Crino, L.; Gridelli, C.; Ricci, S.; Matano E, Boni, C.; Marangolo, M.; Failla, G.; Altavilla, G.; Adamo, V.; Ceribelli, A.; Clerici, M, Di Costanzo, F.; Frontini, L.; Tonato, M. Phase III randomized trial comparing three platinumbased doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20, 4285-4291.
8. Scagliotti, G.V.; Selvaggi, G.; Novello, S.; Hirsch, FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004, 10, 4227s-4232s.
9. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21, 2787-2799.
10. Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabarbara, P.; Seymour, L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353, 123-132. (Pubitemid 41058344)
11. Kurai, J.; Chikumi, H.; Hashimoto, K.; Yamaguchi, K.; Yamasaki, A.; Sako, T.; Touge, H.; Makino, H.; Takata, M.; Miyata, M.; Nakamoto, M.; Burioka, N.; Shimizu, E. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13, 1552-1561.
12. Robert, F.; Blumenschein, G.; Herbst, R.S.; Fossella, F.V.; Tseng, J.; Saleh, M.N.; Needle, M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005, 23, 9089-9096. (Pubitemid 46264008)
13. Thienelt, C.D.; Bunn, P.A., Jr.; Hanna, N.; Rosenberg, A.; Needle, M.N.; Long, M.E.; Gustafson, D.L.; Kelly, K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005, 23, 8786-8793.
14. Rosell, R.; Robinet, G.; Szczesna, A.; Ramlau, R.; Constenla, M.; Mennecier, B.C.; Pfeifer, W.; KJ, O.B.; Welte, T.; Kolb, R.; Pirker, R.; Chemaissani, A.; Perol, M.; Ranson, M.R., Ellis, P.A.; Pilz, K.; Reck, M. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2007, 19, 362-369.
15. Green, M.R.; Kreisman, H.; Doll, D.C.; Lyss, A.P.; Clamon, G.H.; Goutsou, M.; Perry, M.C.; Propert, K.J. Carboplatin in non-small cell lung cancer: an update on the cancer and leukemia group B experience. Semin Oncol 1992, 19, 44-49.
16. Kreisman, H.; Ginsberg, S.; Propert, K.J.; Richards, F.; Graziano, S.; Green, M. Carboplatin or iproplatin in advanced non-small cell lung cancer: a cancer and leukemia group B study. Cancer Treat Rep 1987, 71, 1049-1052.
17. Bonomi, P.D.; Finkelstein, D.M.; Ruckdeschel, J.C.; Blum, R.H.; Green, M.D.; Mason, B.; Hahn R, Tormey, D.C.; Harris, J.; Comis, R.; et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989, 7, 1602-1613.
18. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.;Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92, 205-216. (Pubitemid 30099779)
19. Calvert, A.; Newell, D.; Gumbrell, L.; O'Reilly, S.; Burnell, M.; Boxall, F. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7, 1748-1756.
20. ERBITUX (cetuximab) package insert ImClone Systems Incoporated and Bristol-Meyers Squibb Company. ER-B0001-2005.
21. Cella, D.; Bonomi, A.; Lloyd, S.; Tulsky, D.; Kaplan, E.; Bonomi, P. Reliability and validity of the of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer 1995, 12, 199-200.
22. Soni, M.K.; Cella, D.; Masters, G.A.; Burch, S.P.; Heyes, A.; Silberman, C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer 2002, 4, 153-160.
23. Hanfelt, J.J.; Slack, R.S.; Gehan, E.A. A modification of Simon's optimal design for phase II trials when the criterion is median sample size. Control Clin Trials 1999, 20, 555-566.
24. Cella, D.; Eton, D.T.; Fairclough, D.L.; Bonomi, P.; Heyes, A.E.; Silberman, C.; Wolf, M.K.; Johnson, D.H. What is a clinically meaningful change on the functional assessment of cancer therapylung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol 2002, 55, 285-295.
25. Delbaldo, C.; Michiels, S.; Syz, N.; Soria, J.C.; Le Chevalier, T.; Pignon, J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004, 292, 470-484.
26. Hanna, N.; Lilenbaum, R.; Ansari, R.; Lynch, T.; Govindan, R.; Janne, P.A.; Bonomi, P. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006, 24, 5253-5258.
27. Butts, C.A.; Bodkin, D.; Middleman, E.L.; Englund, C.W.; Ellison, D.; Alam, Y.; Kreisman, H.; Graze, P.; Maher, J.; Ross, H.J.; Ellis, P.M.; McNulty,W.; Kaplan, E.; Pautret, V.;Weber, M.R.; Shepherd, F.A. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007, 25, 5777-5784.
28. Pirker, R.; Pereira, J.R.; Szczesna, A.; von Pawel, J.; Krzakowski, M.; Ramlau, R.; Vynnychenko, I.; Park, K.; Yu, C.T.; Ganul, V.; Roh, J.K.; Bajetta, E.; O'Byrne, K.; deMarinis, F.; Eberhardt,W.; Goddemeier, T.; Emig, M.; Gatzemeier, U. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373, 1525-1531.
29. Lynch, T.J.; Patel, T.; Dreisbach, L.; McCleod, M.; Heim, W.; Hermann, R.C.; Paschold, E.; Pautret, V.; Weber, M.R.; Hart, L.L. Overall survival (OS) results from the phase III trial BMS 099: cetuximab + taxane/carboplatin as 1st-line treatment for advanced NSCLC. J Thorac Oncol 2008, 3(11) (Suppl. 4), S305.
30. Shepherd, F.A.; Dancey, J.; Ramlau, R.; Mattson, K.; Gralla, R.; O'Rourke, M.; Levitan, N.; Gressot, L.; Vincent, M.; Burkes, R.; Coughlin, S.; Kim, Y.; Berille, J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18, 2095-2103. (Pubitemid 30324363)
31. Fossella, F.V.; DeVore, R.; Kerr, R.N.; Crawford, J.; Natale, R.R.; Dunphy, F.; Kalman, L.; Miller, V.; Lee, J.S.; Moore, M.; Gandara, D.; Karp, D.; Vokes, E.; Kris, M.; Kim, Y.; Gamza F, Hammershaimb, L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 2000, 18, 2354-2362. (Pubitemid 30415821)
32. Rosell, R.; Robinet, G.; Szczesna, A.; Ramlau, R.; Constenla, M.; Mennecier, B.C.; Pfeifer, W.; O'Byrne, K.J.; Welte, T.; Kolb, R.; Pirker, R.; Chemaissani, A.; Perol, M.; Ranson, M.R.; Ellis, P.A.; Pilz, K.; Reck, M. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced nonsmall- cell lung cancer. Ann Oncol 2008, 19, 362-369.
33. Borghaei, H.; Langer, C.J.; Millenson, M.; Ruth, K.J.; Litwin, S.; Tuttle, H.; Seldomridge, J.S.; Rovito, M.; Mintzer, D.; Cohen, R.; Treat, J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol 2008, 3, 1286-1292.
34. O'Neil, B.H.; Allen, R.; Spigel, D.R.; Stinchcombe, T.E.; Moore, D.T.; Berlin, J.D.; Goldberg, R.M. High incidence of cetuximabrelated infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007, 25, 3644-3648.
35. Chung, C.H.; Mirakhur, B.; Chan, E.; Le, Q.T.; Berlin, J.; Morse, M.; Murphy, B.A.; Satinover, S.M.; Hosen, J.; Mauro, D.; Slebos, R.J.; Zhou, Q.; Gold, D.; Hatley, T.; Hicklin, D.J.; Platts- Mills, T.A. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008, 358, 1109-1117.
36. Robinson, D.; Mauro, D.; Chung, C.; Fox, F.; Lundberg, M.; Oman, H.; Camacho, T.; Storms,M. Utility of cetuximab-cross reactive IgE as a predictive biomarker for cetuximab associated severe infusion reactions. AACR Meeting Abstracts 2008:B24, 2008.
37. Hirsch, F.R.; Herbst, R.S.; Olsen, C.; Chansky, K.; Crowley, J.; Kelly, K.; Franklin, W.A.; Bunn, P.A.; Jr., Varella-Garcia, M.; Gandara, D.R. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26, 3351-3357.
38. Khambata-Ford, S.; Harbison, C.T.; Hart, L.L.; Awad, M.; Xu, L.; Dakhil, S.; Hermann, R.C.; Lynch, T.J.; Weber, M. K-RAS mutations (MT) and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: results from the BMS099 study. J Thorac Oncol 2008, 3(11) (Suppl. 4), S304.
39. Gatzemeier, U.; von Pawel, J.; Vynnchenko, I.; Zatloukal, P.; De- Marinis, F.; O'Byrne, K.; Eberhardt, W.; Paz-Ares, L.; Emig, M.; Pirker, R. FLEX: cetuximab in combination with platinum-based chemotherapy (CT) improves survival versus CT alone in the 1stline treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2008, 3, S265-abstract 8.